HOME >> MEDICINE >> NEWS
Higher education or larger brain size may protect against dementia later in life, new study finds

set of dementia by keeping their brains active," Dr. Mortimer said. It is not yet known when in the life course formal education needs to occur for this protection to exist, he added.

The research team assessed 294 Catholic sisters for whom data on head circumference were available every year for 10 years. The nuns were tested for their cognitive abilities and completion of daily living tasks, and 111 were diagnosed with dementia. Sixty participants died and their autopsied brains were evaluated to assess the severity of brain abnormalities associated with AD.

The Nun Study, begun in 1992, has followed 678 Catholic sisters, initially 75 to 102 years of age, who are evaluated yearly and who have agreed to brain donation at the time of death. Supported by the National Institute on Aging, it is one of the first large autopsy studies to include normal as well as demented participants. The Nun Study is directed by Dr. David Snowdon of the University of Kentucky. Dr. Snowdon and Dr. William Markesbery, Director of the Sanders-Brown Center on Aging, are co-authors of the current study.


'"/>

Contact: Anne DeLotto Baier
abaier@hsc.usf.edu
813-974-3300
University of South Florida Health
10-Jul-2003


Page: 1 2

Related medicine news :

1. Higher folate intake associated with decreased risk of hypertension in women
2. Higher incidence of rejection following early steroid withdrawal
3. Higher radiation doses help some lung cancer patients live longer
4. Higher doses of cancer drug imatinib proven effective and safe
5. Higher dose of Gleevec leads to increased remission in CML patients
6. Higher cost sharing reduces plans drug expenditures, but boosts enrollee costs
7. Higher nocturnal blood pressure predictive of kidney disease in diabetes
8. First quarter 2002 prescription drug spending: Higher again, but rate of increase drops
9. Higher rate of improvement, lower rate of adverse effects with clarithromycin for acute exacerbations of chronic bronchitis
10. Cancer Rates In Children Of Nuclear Industry Employees No Higher Than General Population In England And Wales
11. New Study Finds Blacks Face 38 Percent Higher Stroke Risk

Post Your Comments:
(Date:2/26/2015)... 2015 marks five years of being ... Caggiano! , Orthodontics is a perfect blend of ... background in biomedical engineering, his artistic talent, his extensive ... dentist allows Dr. Caggiano to create innovative approaches to ... named Orthodontic Products’ Best of 2012, a national recognition, ...
(Date:2/26/2015)... The hip resurfacing procedure at Texas Orthopedics has ... Short to resume his active lifestyle, it has improved his ... Kilimanjaro, the highest free-standing mountain in the world, in an ... late 20s, Short suffered from early onset degeneration. His condition ... bone on bone. , Then about five years ago, ...
(Date:2/26/2015)... CA (PRWEB) February 26, 2015 Beckman ... “Diversity of extracellular vesicles and their cargo in cell-to-cell ... vesicles and their relevance for cell-to-cell communication. The webinar ... March 4, 2015 at 8:00am PT. , Every cell ... extracellular vesicles (EVs) , often called “exosomes” or “microvesicles.” ...
(Date:2/26/2015)... (PRWEB) February 26, 2015 2015 ... is a professional and in-depth study on the ... with a focus on the Chinese situation. ... are Lawton Gmbh & Co.KG, Hu-Friedy, Medisporex, Towne ... Instruments, Shuangyin, Shanghai Weirong Medical Equipment, Shuanglu, Changshu ...
(Date:2/26/2015)... 26, 2015 “ KnowNote ” was featured ... the latest and coolest mobile applications on the iOS, Android, ... host of NewsWatch, conducted the app review and shared with ... in rhythm and in tune. , Learning a musical instrument ... But what if people could take something they already know ...
Breaking Medicine News(10 mins):Health News:Dr. David Caggiano of Caggiano Orthodontics is Celebrating Five Years as an "NJ Top Dentist" ! 2Health News:Dr. David Caggiano of Caggiano Orthodontics is Celebrating Five Years as an "NJ Top Dentist" ! 3Health News:Hip Resurfacing at Texas Orthopedics Enables Patient to Climb Mt. Kilimanjaro 2Health News:Hip Resurfacing at Texas Orthopedics Enables Patient to Climb Mt. Kilimanjaro 3Health News:Beckman Coulter Webinar Series Presents Diversity of Extracellular Vesicles and Their Cargo in Cell-to-cell Communication 2Health News:Beckman Coulter Webinar Series Presents Diversity of Extracellular Vesicles and Their Cargo in Cell-to-cell Communication 3Health News:Global Hemostat Industry Data, Size and Growth Report 2015-2020 Now Available at DeepResearchReports.com 2Health News:Global Hemostat Industry Data, Size and Growth Report 2015-2020 Now Available at DeepResearchReports.com 3Health News:A Modern Way to Learn Music was Featured on NewsWatch Television on January 30, 2015 2
(Date:2/26/2015)... -- ABIVAX, a clinical stage biotech company developing ... it has dosed in New Zealand ... ABX203 which is taking place in several countries of the ... to assess whether ABX203 can deliver a significant improvement in ... load for a much longer period of time when compared ...
(Date:2/26/2015)... Medtronic, Inc. (U.S.), St. Jude Medical, ... in the Saudi Arabia , ... expected to lead the market during the period of 2014 ... player in the market, and owns a wide product portfolio ... Entera Neurostimulator are some of the most popular brands of ...
(Date:2/26/2015)... --  HeartWare International, Inc . (NASDAQ: HTWR ... support technologies that are revolutionizing the treatment of advanced ... the fourth quarter ended December 31, 2014, a 38% ... same period of 2013.  For the fiscal year 2014, ... increase compared to revenue of $207.9 million in 2013.  ...
Breaking Medicine Technology:ABIVAX Recruits First Patient in a Pivotal Phase IIb/III Clinical Trial with ABX203, a Novel Immunotherapy Against Chronic Hepatitis B 2ABIVAX Recruits First Patient in a Pivotal Phase IIb/III Clinical Trial with ABX203, a Novel Immunotherapy Against Chronic Hepatitis B 3ABIVAX Recruits First Patient in a Pivotal Phase IIb/III Clinical Trial with ABX203, a Novel Immunotherapy Against Chronic Hepatitis B 4ABIVAX Recruits First Patient in a Pivotal Phase IIb/III Clinical Trial with ABX203, a Novel Immunotherapy Against Chronic Hepatitis B 5Middle East & Africa Internal Neurostimulation/Neuromodulation Market is Expected to Reach $6.1 Million by 2019, at a CAGR of 17.9% from 2014 to 2019 2Middle East & Africa Internal Neurostimulation/Neuromodulation Market is Expected to Reach $6.1 Million by 2019, at a CAGR of 17.9% from 2014 to 2019 3Middle East & Africa Internal Neurostimulation/Neuromodulation Market is Expected to Reach $6.1 Million by 2019, at a CAGR of 17.9% from 2014 to 2019 4HeartWare International Reports $73.2 Million In Fourth Quarter 2014 Revenue; 38% Increase From Fourth Quarter 2013 2HeartWare International Reports $73.2 Million In Fourth Quarter 2014 Revenue; 38% Increase From Fourth Quarter 2013 3HeartWare International Reports $73.2 Million In Fourth Quarter 2014 Revenue; 38% Increase From Fourth Quarter 2013 4HeartWare International Reports $73.2 Million In Fourth Quarter 2014 Revenue; 38% Increase From Fourth Quarter 2013 5HeartWare International Reports $73.2 Million In Fourth Quarter 2014 Revenue; 38% Increase From Fourth Quarter 2013 6HeartWare International Reports $73.2 Million In Fourth Quarter 2014 Revenue; 38% Increase From Fourth Quarter 2013 7HeartWare International Reports $73.2 Million In Fourth Quarter 2014 Revenue; 38% Increase From Fourth Quarter 2013 8HeartWare International Reports $73.2 Million In Fourth Quarter 2014 Revenue; 38% Increase From Fourth Quarter 2013 9HeartWare International Reports $73.2 Million In Fourth Quarter 2014 Revenue; 38% Increase From Fourth Quarter 2013 10HeartWare International Reports $73.2 Million In Fourth Quarter 2014 Revenue; 38% Increase From Fourth Quarter 2013 11HeartWare International Reports $73.2 Million In Fourth Quarter 2014 Revenue; 38% Increase From Fourth Quarter 2013 12
Cached News: